№ lp_2_3_47133
File format: docx
Character count: 4080
File size: 31 KB
Template insurance appeal letter outlining clinical justification, patient history criteria, and management considerations for multigene hereditary cancer testing in accordance with oncology guideline recommendations.
Title:
Sample Letter of Medical Necessity – MyRisk Hereditary Cancer Test
Type of Document:
Template letter
Purpose:
Insurance coverage request for genetic testing
Test Name:
MyRisk Hereditary Cancer test
Company:
Myriad Genetics
Referenced Organization:
National Comprehensive Cancer Network
Clinical Focus:
Hereditary breast and ovarian cancer; Lynch syndrome; Familial polyposis; hereditary colorectal cancer
Intended Author:
Healthcare provider / Physician
Intended Recipient:
Medical Director
Subject Matter:
Genetic testing; hereditary cancer syndromes; medical management decisions
Referenced Guidelines:
NCCN Clinical Practice Guidelines in Oncology
Consent Requirement:
Informed consent documented
Related Test Panel:
MyRisk Hereditary Cancer test
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Missouri
Topic:
Hereditary Angioedema Treatment
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Health professionals and stakeholders in the MO HealthNet program
Effective Period:
Starting from May 9, 2019
Approval Date:
January 20, 2026
Modification Date:
Not specified
Document Status:
Revision of Existing Criteria
Context:
A proposal outlining the preferred drug list and approval criteria for hereditary angioedema treatment agents within the MO HealthNet program.
Document type:
Press release
Topic:
Rare diseases; hereditary angioedema
Event:
hae day :-)
Date:
16 May
Geographic scope:
Global
Organizing body:
HAE International (HAEi)
Organizational type:
Global non-profit network of patient associations
Target audiences:
General public; healthcare professionals; healthcare decision-makers; industry representatives
Key activity:
Global physical and wellbeing activities converted into steps
Campaign theme:
#active4HAE in purple
Campaign period:
Early April to end of May
Medical condition described:
Hereditary angioedema
Risks described:
Potential fatal airway swelling
Supporting organizations:
National HAE patient organizations
Primary spokesperson cited:
President of HAE International
Online platform referenced:
haeday.org
Press material section:
Notes to editors; About hae day :-); About HAEi
Source type:
Organizational public communication announcing a global health awareness campaign coordinated by an international patient advocacy network and describing planned activities, medical background, and participation framework.
Year:
2026
Region / city:
N/A
Topic:
Hereditary Dystonia
Document type:
Medical classification list
Organization:
N/A
Author:
N/A
Target audience:
Medical professionals, researchers in genetics and neurology
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Document Type:
Letter template
Subject:
Request for approval of Guideline-based Hereditary Cancer Panel
Test Name:
Guideline-based Hereditary Cancer Panel
Test Code:
38611
Provider:
Quest Diagnostics
Referenced Organization:
National Comprehensive Cancer Network
Referenced Guidelines:
NCCN Clinical Practice Guidelines in Oncology
Genes Analyzed:
32 cancer-susceptibility genes
CPT Codes:
Listed in Appendix 2
Appendices:
Appendix 1 (Genes included); Appendix 2 (CPT codes)
Intended Author:
Physician (MD)
Intended Recipient:
Payer / Insurance Provider
Date:
1/18/21
Year:
2019
Region / city:
Cambridge, United Kingdom
Topic:
Hereditary diffuse gastric cancer, endoscopic surveillance, biopsy techniques
Document type:
Clinical Trial Study
Organization / institution:
University of Cambridge
Target audience:
Medical professionals, researchers, and clinicians involved in hereditary cancer surveillance
Period of action:
October 2017 - December 2018
Approval date:
Not specified
Date of changes:
Not specified
Note:
Date
Theme:
Hereditary cancer genetic testing
Document type:
Medical necessity letter
Organization / Institution:
Ambry Genetics Corporation
Author:
Ordering Clinician
Target Audience:
Insurance companies, Utilization Review Department
Period of validity:
Until approved
Year:
2026
Location:
London, UK
Subject:
Distal Hereditary Motor Neuropathy, muscle function, gait analysis, rehabilitation
Document Type:
Participant Information Sheet
Institution:
Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery
Chief Investigator:
Dr Gita Ramdharry
Researcher:
Aljwhara Alangary
Target Audience:
Patients with distal hereditary motor neuropathy
Study Duration:
16 months
Measurement Sessions:
0 months, 12 months, 16 months
Intervention:
4-month therapeutic exercise program, ankle braces, physical therapy
Data Collection Methods:
Gait analysis, muscle strength measurement, MRI scans
Consent Required:
Yes
Confidentiality:
Maintained according to privacy regulations; data may be shared anonymously for future research
Country:
United Kingdom
Topic:
Hereditary angioedema and acquired C1 inhibitor deficiency
Document type:
Medical research article
Study type:
National survey
Authors:
Patrick FK Yong; Tanya Coulter; Tariq El-Shanwany; Tomaz Garcez; Scott Hackett; Rashmi Jain; Sorena Kiani-Alikhan; Ania Manson; Sadia Noorani; Catherine Stroud; Christine Symons; Ravishankar Sargur; Cathal Steele; Hana Alachkar; Ariharan Anantharachagan; Peter D Arkwright; Jolanta Bernatoniene; Malini Bhole; Lindsay Brown; Matthew Buckland; Siobhan Burns; Charu Chopra; James Darroch; Elizabeth Drewe; Jillian Edmonds; Anjali Ekbote; Shuayb Elkhalifa; Sarah Goddard; Dorothea Grosse-Kreul; Padmalal Gurugama; Rosie Hague; Richard Herriot; Archana Herwadkar; Stephen M Hughes; Laura Jones; Sara Lear; Elizabeth McDermott; Sai Hurng Kham Murng; Arthur Price; Vyanka Redenbaugh; Alex Richter; Andrew Riordan; Fiona Shackley; Julia Stichbury; Debbie Springett; Michael D Tarzi; Moira Thomas; Pavaladurai Vijayadurai; Austen Worth
Institutions:
Multiple NHS trusts and university hospitals across England, Scotland, Wales, and Northern Ireland
Corresponding author:
Patrick FK Yong
Corresponding institution:
Frimley Health NHS Foundation Trust
Methodology:
Questionnaire survey of specialist centres managing hereditary angioedema and acquired C1 inhibitor deficiency
Number of participating centres:
37
Patient population:
Individuals with HAE-1/2, HAE with normal C1 inhibitor, and acquired C1 inhibitor deficiency
Sample size:
1265 patients
Medical conditions studied:
Hereditary angioedema; acquired C1 inhibitor deficiency
Key treatments mentioned:
Danazol; C1 inhibitor replacement therapy; icatibant; tranexamic acid
Funding source:
Unrestricted grant from Pharming
Keywords:
hereditary angioedema; acquired C1 inhibitor deficiency; epidemiology; demographics; treatment modalities; United Kingdom
Year:
2026
Region:
International
Topic:
Genetic neurological disorders
Document type:
Reference list
Institution:
Medical genetics research
Authors:
Multiple contributors
Target audience:
Clinicians, researchers, geneticists
Data coverage:
Hereditary myoclonus syndromes, gene associations, clinical features
Classification:
By gene, OMIM number, mode of inheritance
Clinical features included:
Seizures, myoclonus severity, cognitive impairment, ataxia, visual and auditory symptoms
Intended use:
Medical reference for hereditary myoclonus
Source type:
Scientific database and literature compilation
Updated:
Yes
Note:
Year
Theme:
Medical Equipment, Adaptive Devices
Document Type:
Medical Necessity Letter
Target Audience:
Insurance Providers, Medical Professionals
Organization:
Driscoll Health Plan
Document type:
Clinical policy and administrative guidelines
Revision date:
November 1, 2024
Geographic scope:
Texas
Programs referenced:
STAR, STAR Kids, CHIP
Subject area:
Therapy services prior authorization and medical necessity
Target audience:
Therapy providers and referring physicians
Authorization method:
Provider web portal and fax submission
Related forms:
Texas Standard Prior Authorization Request Form for Health Care Services (TARF), Therapy Referral Review by Ordering Physician Attestation Form
Effective policy elements:
Initial evaluations, re-evaluations, continuation of therapy, start of care rules
Coverage criteria:
Medical necessity based on clinical documentation
Source type:
Health plan policy guideline
Year:
2021
Region / City:
United States
Topic:
Medical Necessity Letter, Health Treatment
Document Type:
Medical Document
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, healthcare providers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
California, Arizona
Topic:
Energy Transmission, Public Utilities
Document Type:
Decision
Organization / Institution:
California Public Utilities Commission
Author:
California Public Utilities Commission
Target Audience:
Stakeholders in energy infrastructure and transmission
Effective Period:
N/A
Approval Date:
November 4, 2021
Date of Changes:
N/A
Year:
2025
Region / City:
United States
Theme:
Medical necessity letter
Document type:
Medical letter
Organization / Institution:
Takeda Pharmaceuticals U.S.A., Inc.
Author:
Takeda Pharmaceuticals U.S.A., Inc.
Target audience:
Physicians, insurance providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Date
Diagnosis:
G36.0, neuromyelitis optica [Devic]
Treatment:
UPLIZNA® (inebilizumab-cdon), injection, 1 mg
Reason for request:
Medical necessity for treatment of neuromyelitis optica spectrum disorder (NMOSD) with UPLIZNA
Enclosures:
Prescribing Information, clinical notes, FDA approval letter, patient relapse history, test results, etc.
Year:
2024
Region / City:
United States
Topic:
Medical Necessity Letter
Document Type:
Medical Letter
Organization / Institution:
Bausch + Lomb
Author:
Physician
Target Audience:
Healthcare providers, Payers
Action Period:
June 2024
Approval Date:
June 2024
Modification Date:
N/A
Document type:
Medical necessity letter
Therapeutic area:
Ophthalmology
Indication:
Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Medication name:
VYZULTA (latanoprostene bunod ophthalmic solution)
Dosage strength:
0.024%
Drug class:
Prostaglandin analogue with nitric oxide–donating activity
Regulatory status:
FDA-approved prescription medication
Manufacturer:
Bausch & Lomb Inc.
Intended recipient:
Health insurance payer or medical director
Target population:
Patients with open-angle glaucoma or ocular hypertension
Clinical evidence referenced:
Phase 2 VOYAGER study; Phase 3 APOLLO and LUNAR studies; real-world retrospective studies
Safety information included:
Yes
References:
Peer-reviewed journals and prescribing information
Source type:
Industry-provided informational material
Year:
2025
Region / City:
Princeton, NJ
Theme:
Medical necessity documentation
Document Type:
Medical letter
Organization / Institution:
Bristol-Myers Squibb Company
Author:
<>
Target Audience:
Healthcare professionals, physicians
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Jurisdiction:
West Virginia, United States
Type of document:
Legislative Act
Governing body:
West Virginia Legislature
Authors:
Delegates Riley, Linville, D. Cannon, Eldridge
Effective date:
April 11, 2025
Subject:
Public utilities regulation, water and sewer services, certificate of public convenience and necessity
Legal references:
§24-2-11, §31-15A-1 et seq. of the West Virginia Code
Scope:
Construction projects of water and sewer services for utilities with at least 4,500 customers and $3 million or more in annual revenues
Approval authority:
Public Service Commission, Infrastructure and Jobs Development Council
Decision timelines:
Standard projects 225–270 days, projects >$50 million 400 days
Year:
2023
Region / City:
United States
Subject:
Healthcare
Document Type:
Template
Institution / Organization:
Takeda Oncology
Author:
Takeda Oncology
Target Audience:
Healthcare providers, insurance companies
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified